Literature DB >> 31094943

Psoriasiform Dermatitis After Initiation of Treatment with Dupilumab for Atopic Dermatitis.

Emilie Fowler, Jonathan I Silverberg, Joshua D Fox1, Gil Yosipovitch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31094943     DOI： 10.1097/DER.0000000000000481

Source DB:  PubMed          Journal:  Dermatitis        ISSN： 1710-3568            Impact factor:   4.845


× No keyword cloud information.
  6 in total

1.  Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series.

Authors:  L E M de Wijs; N T Nguyen; A C M Kunkeler; T Nijsten; J Damman; D J Hijnen
Journal:  Br J Dermatol       Date:  2019-12-22       Impact factor: 9.302

Review 2.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

3.  Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients.

Authors:  Young Jae Kim; Mi Young Lee; Chong Hyun Won
Journal:  Asia Pac Allergy       Date:  2022-01-10

4.  Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab.

Authors:  Kamran Ali; Liming Wu; YunMi Qiu; Menghua Li
Journal:  Front Med (Lausanne)       Date:  2022-07-28

5.  Tumor Necrosis Factor Inhibitor-Induced Eczematous Eruption: A Report of Two Cases and Review of the Literature.

Authors:  Sohemi Pagan-Leon; Tyler Werbel; Marjorie Montanez-Wiscovich
Journal:  Cureus       Date:  2021-05-17

6.  Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis.

Authors:  Aakaash Varma; Jacob Levitt
Journal:  JAAD Case Rep       Date:  2020-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.